| A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors M Candelaria, D Gallardo-Rincón, C Arce, L Cetina, JL Aguilar-Ponce, ... Annals of Oncology 18 (9), 1529-1538, 2007 | 296 | 2007 |
| Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy B Segura-Pacheco, C Trejo-Becerril, E Perez-Cardenas, L Taja-Chayeb, ... Clinical Cancer Research 9 (5), 1596-1603, 2003 | 295 | 2003 |
| A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes P Zambrano, B Segura-Pacheco, E Perez-Cardenas, L Cetina, ... BMC cancer 5, 1-12, 2005 | 201 | 2005 |
| A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer C Arce, C Pérez-Plasencia, A González-Fierro, E de la Cruz-Hernández, ... PloS one 1 (1), e98, 2006 | 171 | 2006 |
| Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study A Chavez-Blanco, B Segura-Pacheco, E Perez-Cardenas, L Taja-Chayeb, ... Molecular cancer 4, 1-9, 2005 | 170 | 2005 |
| Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines A Chavez-Blanco, C Perez-Plasencia, E Perez-Cardenas, ... Cancer cell international 6, 1-9, 2006 | 163 | 2006 |
| A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results J Coronel, L Cetina, I Pacheco, C Trejo-Becerril, A González-Fierro, ... Medical oncology 28, 540-546, 2011 | 159 | 2011 |
| Cancer progression mediated by horizontal gene transfer in an in vivo model C Trejo-Becerril, E Pérez-Cárdenas, L Taja-Chayeb, P Anker, ... PloS one 7 (12), e52754, 2012 | 157 | 2012 |
| Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy A Schcolnik-Cabrera, A Chávez-Blanco, G Domínguez-Gómez, ... Expert opinion on investigational drugs 27 (5), 475-489, 2018 | 93 | 2018 |
| Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial M Candelaria, A Herrera, J Labardini, A González-Fierro, C Trejo-Becerril, ... Annals of hematology 90, 379-387, 2011 | 81 | 2011 |
| Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients C Trejo‐Becerril, E Pérez‐Cárdenas, H Treviño‐Cuevas, L Taja‐Chayeb, ... International journal of cancer 104 (6), 663-668, 2003 | 73 | 2003 |
| DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells M Candelaria, E de La Cruz-Hernandez, L Taja-Chayeb, ... PLoS One 7 (3), e29181, 2012 | 56 | 2012 |
| Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate A Chávez-Blanco, D la Cruz-Hernández, GI Dominguez, ... International journal of oncology 39 (6), 1491-1499, 2011 | 52 | 2011 |
| Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma A Dueñas-González, C López-Graniel, A González, E Gomez, L Rivera, ... American journal of clinical oncology 26 (1), 22-25, 2003 | 40 | 2003 |
| Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma D la Cruz-Hernández, C Perez-Plasencia, E Pérez-Cardenas, ... Oncology reports 25 (2), 399-407, 2011 | 39 | 2011 |
| Pharmacogenetics and pharmacoepigenetics of gemcitabine M Candelaria, E De la Cruz-Hernández, E Perez-Cardenas, ... Medical oncology 27, 1133-1143, 2010 | 37 | 2010 |
| Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. M Candelaria, L Cetina, E Perez-Cardenas, E De La Cruz-Hernández, ... Eur. J. Gynaec. Oncol.-ISSN 31 (4), 2010, 2010 | 37 | 2010 |
| Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model C Trejo-Becerril, E Pérez-Cardenas, B Gutiérrez-Díaz, ... Integrative cancer therapies 15 (4), NP35-NP43, 2016 | 30 | 2016 |
| Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the … A Gonzalez-Fierro, D Vasquez-Bahena, L Taja-Chayeb, S Vidal, ... International Journal of Clinical Pharmacologyand Therapeutics 49 (8), 519, 2011 | 23 | 2011 |
| Feasibility and antitumor efficacy in vivo, of simultaneously targeting glycolysis, glutaminolysis and fatty acid synthesis using lonidamine, 6‑diazo‑5‑oxo‑L‑norleucine and … D Cervantes‑Madrid, G Dominguez‑Gomez, A Gonzalez‑Fierro, ... Oncology letters 13 (3), 1905-1910, 2017 | 22 | 2017 |
Alfonso Duenas-GonzalezUnit of Biomedical Research on Cancer, Instituto de Investigaciones Biomedicas UNAM, InstitutoVerified email at incan.edu.mx
